EP
GBT

Eversept Partners’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Eversept Partners’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-40,000
Closed -$1.4M – 127
2021
Q2 		$1.4M Buy
+40,000
New +$1.56M 0.09% 73

Other funds holding GBT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Eversept Partners's GBT Position: Q3 2018 in Review

Eversept Partners sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2018, closing a stake of 13,800 shares — an estimated $624K sold.

Eversept Partners first reported a position in GBT in Q4 2017 and held it in 3 quarters. The position peaked at $1.53M in Q4 2017. 184 funds tracked by Wall St. Rank hold GBT as of Q3 2018.

  • Eversept Partners reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2018 after selling out during the quarter.
  • Eversept Partners sold 13,800 Global Blood Therapeutics, Inc. shares in Q3 2018, an estimated $624K.
  • Eversept Partners first reported a position in Global Blood Therapeutics, Inc. in Q4 2017 and held it in 3 quarters.
  • Eversept Partners's Global Blood Therapeutics, Inc. position peaked at $1.53M in Q4 2017.
  • 184 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2018.

Based on Eversept Partners's 13F filing for Q3 2018, filed 14 Nov 2018.